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before treatment. Analysis of ΔPPFP that represents the difference between PPFP after and before treatment
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perspective of using FC-ALPA and FC-AFPA as a useful serologic tool for diagnosis and for post-therapeutic
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Leishmaniasis encompasses multiple clinical syndromes, most
notably, visceral, cutaneous, and mucosal forms. Localized cutaneous
leishmaniasis (LCL) is a disease associated with infections caused by
several species of the genus Leishmania (Grimaldi and Tesh, 1993).
Clinical manifestations depend on the parasite factors, the epidemio-
logic characteristic of the vector and the host genetic and immunologic
constitution (Rogers et al., 2002). Cutaneous leishmaniasis is a serious
public health problemand it is endemic toBrazil, particularly in the state
of Pernambuco, where Leishmania (Viannia) braziliensis is known as the
major circulating species (Brito et al., 2009).
At present, there is not a gold-standard test for cutaneous
leishmaniasis and, frequently, a combination of different diagnosis
techniques is needed to obtain more precise results. Thus, the
diagnosis is performed by the association of clinical, epidemiologic,and laboratorial aspects. These techniques include amastigote
identiﬁcation through tissue immunocytochemical techniques,
“imprints” (printing by biopsy apposition), in aspirated lesion and
in histopathologic evaluation, besides the promastigote identiﬁcation
in vitro. The indirect immunoﬂuorescence (IIF), enzyme-linked
immunosorbent assay (ELISA), and Western blot, based on the
presence of speciﬁc antibodies against parasite antigens, are the
serologicmethods used.Montenegro skin test is a late hypersensitivity
test based on the immunity mediated by cells. At the same time, there
has been a notable improvement in such techniques as polymerase
chain reaction (PCR), real-time PCR, and ﬂow cytometry, with the
objective of increasing sensitivity and speciﬁcity (Vega-López, 2003).
The traditional laboratory methods have several limitations and
present difﬁculties. Furthermore, immunoassays can show low
antibody titers, due to a cross reactivity with Trypanosoma cruzi that
depends on the antigen as well as the lack of well-standardized
procedures used to detect the speciﬁc antibodies. Moreover, antibody
production after treatment is not yet clear and the predictive value of
lower or higher levels against speciﬁc antigenic fractions during
follow-up is not well deﬁned (Brito et al., 2001).
Chemotherapy treatment is based primarily on the administra-
tion of pentavalent antimonials. These antimonials are highly toxic
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period. Besides toxicity, one of the limitations in the treatment is the
absence of an objective cure criterion. The cure criterion adopted by
many authors is the complete healing of the lesion. Nevertheless,
this is an unsatisfactory criterion, as the reactivation of the lesions
may occur even after the treatment (Gontijo and Carvalho, 2003;
Mendonça et al., 2004; Schubach et al., 1998). Therefore, these facts
point to the need for new tools that can help determine prognostics
and efﬁcient diagnosis of cutaneous leishmaniasis.
More recently, a ﬂow-cytometry analysis has been described for
diagnostic purposes. The anti-live promastigote antibodies (FC-ALPA-
IgG) detected through this method showed high sensitivity and
speciﬁcity applicable in the diagnosis of LCL (Rocha et al., 2002, 2006).
This study opens new perspectives for the use of FC-ALPA-IgG in the
response evaluation of novel therapeutic protocols.
Based on that, in the present study, we report the use of ﬂow
cytometry–based methods for the assessment of humoral response
against live and ﬁxed L. (Viannia) braziliensis promastigote forms.
Herein, we propose to investigate the performance of FC-ALPA-IgG
and FC-AFPA-IgG (anti-ﬁxed promastigote antibodies) to monitor the
post-therapeutic cure of LCL patients, comparing the IgG reactivity
before and after speciﬁc treatment.
2. Population, materials, and methods
2.1. Study population
A total of 30 patients with localized cutaneous leishmaniasis
(LCL; ages ranging from 14 to 83 years [mean = 26 ± 16.5 years],
including 20 males and 10 females) from endemic areas of the state
of Pernambuco (Amaraji and Moreno municipalities) were evaluated
on clinical and epidemiologic features and laboratory criteria. All
patients showed positive diagnoses for LCL, including direct parasite
detection, Montenegro skin test, indirect immunoﬂuorescence, and
PCR. Serum samples were collected from all LCL patients before the
treatment onset.
All patients received the standard treatment for LCL, carried out
with N-methyl glucamine antimoniate (Glucantime®; Sanoﬁ-Aventis
Farmacêutica Ltda, Suzano, Brazil), and the therapeutic scheme was
made of doses of 20 mg/kg per day through subcutaneous injections
during 30 days. The occurrence of adverse reactions was monitored
throughout the treatment period. After treatment, sera samples were
collected from all patients in a cross-sectional investigation with
intervals ranging from 1 to 24months, further grouped into 1–3months
(n=4), 4–7months (n=14), and 12–24months (n=12). All patients
underwent blood collection twice: prior to and after the end of
chemotherapy treatment with Glucantime®.
Eight sera samples from healthy individuals from nonendemic areas
and without previous LCL infection were used as a control for
noninfected individuals (NI). All of them signed the “Terms of Free
and Informed Consent,” and the CPqAM/Fiocruz Research Ethics
Committee (Protocol no. 27/04) approved the experimental protocols.
2.2. Parasite preparation
L. (V.) braziliensis promastigote forms (MHOM/BR/75/2903) were
cultivated in liver infusion tryptose medium (LIT) at 24 ± 1 °C. After
serial passage in vitro, the parasites, in stationary phase, were
collected and homogenized in a low-rotation vortex to dissolve
clumps. All procedures were performed aseptically in a biohazard
hood. The homogenate was centrifuged at 100 × g for 10 min to
remove cell debris. Prior to the recovery of the parasite suspension,
the supernatant was left to rest for 10min at room temperature. Then,
the supernatant was transferred to another tube and centrifuged at
1000 × g for 10 min at 4 °C. The pellet of parasites was suspended in a
buffer (pH 7.2) containing 10% heat-inactivated fetal bovine serum(phosphate buffered saline [PBS]–10% FBS) (Gibco, Grand Island, NY,
USA) and centrifuged at 1000 × g for 10 min. Two distinct parasite
preparations were used to evaluate the anti–L. (V.) braziliensis IgG
reactivity referred to as “live” and “ﬁxed” promastigote suspensions.
For the live promastigote suspension, parasites were immediately
resuspended in PBS–10% FBS and used for the immunoﬂuorescence by
ﬂow cytometry. For the ﬁxed promastigote suspension, the parasites
were resuspended in equal volumes of PBS and ﬁx solution (per liter,
10 g of paraformaldehyde, 10.2 g of sodium cacodylate, and 6.65 g of
sodium chloride, pH 7.2; Sigma, St. Louis, MO, USA) and stored
overnight at 4 °C. The ﬁxed promastigotes were washed in PBS and
stored at 4 °C until use. Both parasite suspensions were counted in a
Neubauer hemocytometer chamber and the concentration adjusted to
5 × 106/mL. The live or ﬁxed promastigotes were used separately in
the immunoﬂuorescence assays by ﬂow cytometry.
2.3. Immunoﬂuorescence by ﬂow cytometry
The immunoﬂuorescence assays for detecting anti-live (FC-ALPA-
IgG) and anti-ﬁxed (FC-AFPA-IgG) L. (V.) braziliensis IgG antibodies
were performed as described by Rocha et al. (2002). A suspension of
live or ﬁxed parasites (2.5 × 105/well) was incubated in 96-well,
round-bottom, polystyrene plates at 37 °C for 30 min in the presence
of different dilutions (1:128 to 1:16,384 for FC-ALPA-IgG and 1:256 to
1:32,768 for FC-AFPA-IgG) of serum samples. After incubation with
the test sera samples, the parasites were washed twice with 150 μL of
PBS–10% FBS (at 1000 × g for 10min at 4 °C). Afterwards, the parasites
were reincubated at 37 °C for 30 min in the dark, in the presence of
ﬂuorescein isothiocyanate (FITC)–conjugated anti-human IgG anti-
body (Sigma) diluted at 1:1200 in PBS–10% FBS for live parasites and
at 1:16,000 for ﬁxed parasites. After a second wash procedure, the
FITC-labeled parasites were ﬁxed for 30 min with a FACS ﬁx solution
(per litre, 10 g of paraformaldehyde, 10.2 g of sodium cacodylate, and
6.65 g of sodium chloride, pH 7.2; Sigma) before being analyzed in the
cytometer. Flow cytometry measurements were performed in a
maximum period of 24 h after parasites ﬁxation. Each assay included
an internal control of nonspeciﬁc binding in which parasites not
exposed to human serum were incubated with FITC-conjugated anti-
human IgG. In all experiments positive and negative LCL control
samples were included. The positive control chosen was a patient's
serum with parasitological, immunological and molecular diagnostics
all positive for LCL. The optimum working concentration of sera and
anti-human antibody conjugates was determined with the checker-
board titration method as previously proposed by Rocha et al. (2002).
All FC-ALPA and FC-AFPA tests were repeated and conﬁrmed, assuring
the repeatability of the test.
2.4. Flow cytometry data acquisition and analysis
Flow cytometry acquisition was performed using the FACSCalibur™
equipment (Becton Dickinson, São Paulo, Brazil). The Cell-Quest™
software (Becton Dickinson) packagewas used in both data storage and
analysis. Stained parasiteswere run in the cytometer, and 10,000 events
per samplewere acquired. Promastigoteswere identiﬁed based on their
speciﬁc forward (FSC) and side (SSC) light scattering properties.
Following FSC and SSC gain adjustments, parasites were found by
assuming a characteristic FSC × SSC dot plot distribution. The relative
FITC ﬂuorescence intensity of each event was analyzed with a single
histogram representation. A marker was set up on the histogram
representation of the FITC-conjugated internal control and used in all
data analysis reported here to determine, for each sample, the
percentage of positive ﬂuorescent parasites (PPFP) as previously
described by Rocha et al. (2002). The receiver operating characteristic
curve - ROC curve (Greiner et al., 2000) was used to select the cut-off
value to discriminate between positive and negative results of FC-ALPA-
IgG and FC-AFPA-IgG. The analysis of paired ΔPPFP, deﬁned as the
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was used as a new approach to monitor post-therapeutic IgG reactivity
in LCL as proposed by Lemos et al. (2007) to monitor patients with
visceral leishmaniasis.
3. Results
3.1. Initial serum screening
In the ﬁrst step of this study, we analyzed the anti–L. braziliensis
IgG reactivity proﬁle for live (FC-ALPA) and ﬁxed (FC-AFPA) antigen
preparations, aiming to characterize the titration curve and the serum
dilution to differentiate LCL patients and noninfected individuals. Data
analysis showed that both antigen preparations, FC-ALPA-IgG and FC-
AFPA-IgG, have the same titration curves and patterns of reactivity
(PPFP values). This analysis identiﬁed the speciﬁc serum dilution
(1:1024 for FC-ALPA-IgG and FC-AFPA-IgG) that best segregates the
PPFP values of LCL patients and noninfected individuals. As observed
in Fig. 1, the results were classiﬁed as positive with PPFP ≥60% and as
negative with PPFP ≤60%. This percentage was done according to
Martins-Filho et al. (1995), from the analysis of antibody titration
curves of individual serum expressed by the mean of PPFP values. The
initial screening showed that sera were considered negative (PPFP
≤60%) when reacting in a dilution of 1:128 to 1:16,384 for FC-ALPA-
IgG and 1:512 to 1:32,768 for FC-AFPA (Fig. 1). In view of these results,
FC-ALPA-IgG and FC-AFPA-IgG were able to discriminate the IgG
reactivities of patients compared to the control group.
3.2. Performance of anti-live and ﬁxed L. (V.) braziliensis IgG reactivity
to identify active LCL
In this step, we evaluated the test performance to identify patients
with active LCL. Thus, sera were separated and reactivity was
determined with a dilution of 1:1024 and a cut-off value of PPFP
60% (Fig. 1). Using this approach, the sensitivity of FC-ALPA-IgG and
FC-AFPA-IgG was 86% and 90%, respectively. The speciﬁcity was 78%,
showing a cross-reactivity of 22% for both parasite preparations (live
and ﬁxed) (Fig. 2). The results obtained in this evaluation showedA
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Fig. 1. Anti-live FC-ALPA-IgG (A) and anti-ﬁxed FC-AFPA-IgG (B) L. (V.) braziliensis IgG react
and from noninfected individuals (NI =○). The results are expressed as mean percentage of
IgG and 1:256 to 1:32,768 for FC-AFPA-IgG. The rectangles represent the selected serum dilu
FC-ALPA-IgG and FC-AFPA-IgG).that, despite the cross-reactivity observed for NI samples, FC-ALPA-
IgG and FC-AFPA-IgG have an important value in identifying LCL cases.
Additionally, we analyzed the applicability of FC-ALPA-IgG and FC-
AFPA-IgG to monitor the post-therapeutic cure of LCL. The analysis of
PPFP values performed after treatment did not demonstrate the
applicability of this parameter for post-therapeutic cure assessment at
a serum dilution of 1:1024. No signiﬁcant changes in the PPFP values
at serum dilution 1:1,024 were observed after treatment showed
reactivity less than 60% to FC-ALPA-IgG and FC-AFPA-IgG (Fig. 3).
Further comparative analysis used the PPFP values of paired
samples evaluated before and after treatment along the titration
curves (1:2048 to 1:16,384 for FC-ALPA-IgG and 1:2048 to 1:32,678
for FC-AFPA-IgG). Our data demonstrated that only FC-ALPA-IgG led
to differential reactivity when comparing the mean PPFP values
observed before and after treatment (Fig. 4, asterisks).
3.3. Introducing ΔPPFP as a new strategy applied to post-therapeutic
cure assessment in LCL
As the analysis of PPFP values performed after treatment did not
demonstrate any applicability for post-therapeutic cure assessment at
a sera dilution of 1:1024, we searched for a new tool to comparatively
analyze the IgG reactivity before and after treatment.
The proposed strategy was to analyze the differential PPFP
reactivity detected by paired samples (delta reactivity [Δ]). In the
present study, we used anti-Leishmania IgG reactivity ΔPPFP which
represents the difference between PPFP after treatment and PPFP
before treatment (ΔPPFP = PPFPAT− PPFPBT). Initially, we evaluated
the ΔPPFP values throughout the FC-ALPA-IgG and FC-AFPA-IgG
titration curves, aiming to identify the serum dilution ranges of
1:2048 to 1:16,384 for FC-ALPA-IgG and 1:2048 to 1:32,678 for FC-
AFPA-IgG that represent the highest differential reactivities (Fig. 5).
As shown in Fig. 5, the FC-ALPA-IgG at a sera dilution of 1:8192
showed that 81% of the treated patients displayed negative ΔPPFP
values, demonstrating a decrease in the IgG reactivity after treatment.
Moreover, the FC-AFPA-IgG at a sera dilution of 1:4096 was able to
identify 61% of patients with negative ΔPPFP values. Consequently,
these dilutions were the best choices to analyze the ΔPPFP values for
FC-ALPA-IgG and FC-AFPA-IgG, respectively.B
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Fig. 2. Anti-live FC-ALPA-IgG (A) and anti-ﬁxed FC-AFPA-IgG (B) L. (V.) braziliensis IgG reactivity in serum samples from patients with LCL (●) and from NI (○). The results are
expressed as individual PPFP at a serum dilution of 1:1024. The dashed line represents the cut-off between negative and positive results.
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values, we investigated whether the time after treatment would
interfere in the performance of this new strategy of post-therapeutic
follow-up. For this purpose, the treated patients were categorized into
3 subgroups based on the time (months) after treatment (mAT) when
they were evaluated: 1–3 mAT, 4–7 mAT, and 12–24 mAT. Data
analysis was performed after the establishment of a gray zone
corresponding to the ﬁrst quartile of the ΔPPFP range (cut-off edge of
25%, considering PPFP values from 0 to 100%) according to Lemos et al.
(2007). We believe that the use of this gray zone would give further
strength to data interpretation since it would avoid interference
regarding thepossible intrinsicﬂowcytometrymeasurement variability.
Our data demonstrated that 75% of the patients evaluated at 1–3 mAT
showednegativeΔPPFP values detectedby FC-ALPA-IgG,whereas25%of
them showed negative ΔPPFP values detected by FC-AFPA-IgG. Patients
evaluated at 4–7 mAT displayed 43% and 29% of negative ΔPPFP valuesA
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Fig. 3. Comparative reactivity of anti-live FC-ALPA-IgG (A) and anti-ﬁxed FC-AFPA-IgG (B) L.
(BT = ●) and after treatment (AT = ). The results are expressed as individual PPFP at a s
positive results.detected by FC-ALPA-IgG and FC-AFPA-IgG, respectively. When ΔPPFP
reactivity was evaluated at 12–24 mAT, 58% and 33% of the patients
presented negative results in FC-ALPA-IgG and FC-AFPA-IgG, respec-
tively (Fig. 6).
4. Discussion
One of the major limitations in the use of serologic approaches in
the diagnosis and cure assessment of cutaneous leishmaniasis is the
scarcity of sensitive methods to discriminate the IgG reactivity during
active infection and the residual serologic reactivity after effective
treatment. In general, the diagnosis and the cure criterion are based
on clinical and epidemiologic ﬁndings, and complete therapeutic
effectiveness is considered when complete lesion healing is observed.
Nevertheless, this is an unsatisfactory criterion, as lesion reactivation
may occur even after treatment and complete healing of the initialB
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are usually susceptible to antimonial treatment and healing occurs at
the end of therapy, the occurrence of more than 90% of relapses up to
1 year in LCL strengthens the suggestion of clinical control for at least 1
year post treatment (Coutinho et al., 1996).
In this context, it has been suggested that the decrease in anti-
Leishmania antibodies titer in serum of patients after treatment
could be an alternative method to monitoring speciﬁc post-
therapeutic cure (Chiari et al., 1973, Mendonça et al., 1988).
Moreover, the presence of anti-Leishmania antibodies after treat-
ment could indicate the persistence of the parasite and be a
predictive factor in cutaneous leishmaniasis recurrence (Saravia
et al., 1989). Associated with these aspects, the existence of various
parasite species and vector, as well as parasite–host relation,
represents important elements related to cutaneous leishmaniasis
complexity. This fact ponts to the need for new tools that help to
determine prognostics and an efﬁcient diagnosis.A
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In this study, we have evaluated the applicability of an indirect
immunoﬂuorescence assay based on ﬂow cytometry methodology to
detect anti-live and anti-ﬁxed L. (Viannia) braziliensis promastigote
IgG for the serologic diagnosis of LCL. In addition, we have veriﬁed the
applicability of the serologic reactivity to assess post-therapeutic cure
in cured patients after different periods following treatment with
pentavalent antimonial chemotherapy. The rationale underlying our
experimental design was the fact that the live promastigote
preparation would represent a useful tool to work with a selective
set of antigens (outer membrane epitopes) and contribute to a more
reﬁned analysis. However, the labile nature of this antigenicB
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practice. On the other hand, although the use of ﬁxed promastigotes
represents a feasible way to produce and store a bulk amount of pre-
ﬁxed antigen that contributes to large-scale production, it would
contribute to the development of a larger amount of intracytoplasmic
epitopes and complicate the observation of minor changes in the
serologic reactivity following therapeutic intervention (Pissinate
et al., 2008).
Another important aspect of the serologic methods applied to
the cutaneous leishmaniasis diagnosis is the choice of antigen
sources, which still represents a relevant obstacle. When total
promastigotes are used as antigen, it is common to ﬁnd false-
positive reactions due to cross-reactions with other diseases. It is
important to investigate alternative preparations to detect Leish-
mania antibodies (Celeste et al., 2004; Gonçalves et al., 2002). In the
present investigation, we have chosen the L. (V.) braziliensis
promastigotes as the antigenic source to access IgG reactivity in
LCL patients. Although this species is very difﬁcult to grow in vitro,
requiring the use of axenic cultures, complex medium composition
and ﬁne pH and temperature control (Lemesre et al., 1988), L. (V.)
braziliensis is the most important LCL causative agent in Brazil and
especially in the Brazilian state of Pernambuco.
A diagnostic method based on ﬂow cytometry to detect anti-live
L. (V.) braziliensis antibodies has been described by Rocha et al.
(2002, 2006). They demonstrated 96% sensitivity for FC-ALPA-IgG
L. braziliensis in active patients. Using ﬁxed L. amazonensis
promastigotes, Pissinate et al. (2008) showed a good performance
of FC-AFPA-IgG in the serologic diagnosis of LCL. However, they
found cross-reactivity with other co-endemic diseases, like trypa-
nosomatidae infections. Our data demonstrated that both methods
display low speciﬁcity and still require methodological adjustments
in order to improve their performance as a conﬁrmatory diagnostic
tool. In fact, Rocha et al. (2002) and Pissinate et al. (2008) have
already demonstrated that the occurrence of false-positive results in
FC-ALPA-IgG and FC-AFPA-IgG in endemic areas mostly related to
the cross-reactivity of sera samples from patients with Chagas
disease and visceral leishmaniasis, co-endemic diseases generally
observed in areas of prevalent cutaneous leishmaniasis.
In our study, we found that FC-ALPA-IgG using L. (V.) braziliensis
displayed 86% sensitivity, whereas FC-AFPA-IgG showed 90% sensi-tivity for the diagnosis of LCL. The difference obtained could be
explained by the heterogeneity of Leishmania (V.) spp in Brazil. Brito
et al. (2009) demonstrated the presence of 10 circulating zymodemes
in the well-deﬁned “Zona da Mata” region of Pernambuco. The
heterogeneity observed among L. (V.) braziliensis parasites from this
region is noteworthy, particularly in contrast to the homogeneity of
parasites isolated from other regions of Brazil (Brandão-Filho et al.,
2003; Brito et al., 1993; Cupolillo et al., 2003).
The results obtained showed that both techniques (FC-ALPA-IgG
and FC-AFPA-IgG) are useful for the serodiagnosis of LCL as
compared to the conventional immunoﬂuorescence assay. Although
FC-AFPA-IgG displays a slightly higher sensitivity in the diagnosis of
LCL, the FC-ALPA-IgG seems to be more reliable for cure monitoring,
being able to identify more differences between IgG reactivity
before and after treatment when assessed by ΔPPFP. We found 81%
of the treated patients with negative ΔPPFP results for FC-ALPA-IgG
compared to 61% with negative ΔPPFP for FC-AFPA-IgG. These
results show that FC-ALPA-IgG represents better performance than
FC-AFPA-IgG for post-therapeutic monitoring of LCL patients. We
have a general belief that FC-ALPA-IgG represents better perfor-
mance than FC-AFPA-IgG as previous studies of our group have
demonstrated a real advantage of using live instead of ﬁxed
parasites in serologic approaches applied to the diagnosis and cure
assessment of human protozoa (Martins-Filho et al., 1995, 2002;
Pissinate et al., 2008; Vitelli-Avelar et al., 2007). In fact, the use of
live promastigotes seems to represent a better tool to achieve better
performance in serologic approaches since in this antigenic
preparation only the outer membrane epitopes are available for
IgG binding, in contrast to the ﬁxed antigenic preparation in which
the cytoplasmic antigens are also available for IgG recognition. The
use of a selected set of outer membrane antigens is a good strategy
to work with a more restricted IgG repertoire that would potentially
ﬁnd slight differences resulting from the loss of B-cell clones early
after effective etiologic treatment.
We have further investigated whether the performance would be
inﬂuenced if the test was performed at different times after treatment.
For this purpose, serum samples collected after treatment were
segregated into 3 groups referred to as 1–3 mAT, 4–7 mAT, and 12–24
mAT. The FC-ALPA-IgG and FC-AFPA-IgGwere assayed, and the ΔPPFP
values were generated to monitor seroreactivity at different times
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of ΔPPFP to demonstrate differential reactivity according to the time
after treatment. However, FC-ALPA-IgG still demonstrated better
performance as compared to FC-AFPA-IgG, leading to higher fre-
quency of cases with negative ΔPPFP. It is important to mention that
the low performance of ΔPPFP to detect differential reactivity in this
cross-sectional investigation should not be considered the end point
of using this parameter for cure assessment in LCL, since this approach
would be better evaluated in a longitudinal investigation in order to
generate more accurate data for cure assessment in LCL.
Although most ﬂow cytometry–based methods still represent
higher cost compared to conventional methods, such as immunosor-
bent and immunoﬂuorescence assay, the possibility of working with a
microplate serologic approach has reduced the ﬁnal cost of a given
test. Moreover, at the present time, several clinical laboratories in
developing countries are considering the acquisition of ﬂow
cytometers. Therefore, in the near future, the implementation of
new ﬂow cytometry-based tests will became routine as will the
interchange between research centers and clinical laboratories. In our
experience, ﬂow cytometry–based serologic approaches present good
reproducibility and outstanding concordance among independent
analysts (Garcia et al., 2009).
In conclusion, our data suggested that the new ﬂow cytometry–
based methodology has promising potential to identify active LCL
clinical cases in patients. Further longitudinal studies are currently
under investigation in order to better characterize the approach to for
monitoring post-therapeutic cure as well as to obtain the clinical
values of this new approach and to validate its use in medical studies.
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